Xultophy 100/3.6

The dosage of Insulin Degludec must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals.

• For Type 1 Diabetes: Insulin Degludec is typically used as the basal component of a basal-bolus regimen. The starting dose is generally approximately one-third to one-half of the total daily insulin requirement. The remainder of the daily insulin should be administered as a short-acting or rapid-acting insulin before meals.
• For Type 2 Diabetes: For patients naive to insulin, the recommended starting dose is 10 units once daily. For patients switching from other basal insulins, the starting dose is usually the same as the previous basal insulin dose (a 1:1 conversion), though some clinicians may reduce the dose by 20% when switching from twice-daily basal insulin to ensure safety.

Dosage adjustments should be made gradually, typically no more frequently than every 3 to 4 days, to allow the drug to reach a new steady state.

Insulin Degludec is approved for use in children and adolescents aged 1 year and older with Type 1 or Type 2 diabetes.

• Starting Dose: Similar to adults, the dose must be individualized. In pediatric Type 1 diabetes, the basal dose is usually 1/3 to 1/2 of the total daily insulin dose.
• Conversion: When switching from other basal insulins to Insulin Degludec in pediatric patients, a 1:1 conversion is standard, but close monitoring of blood glucose is required during the transition period.
• Safety: It has not been studied in children under 1 year of age.

Renal Impairment

Patients with kidney disease (renal impairment) may require more frequent dose adjustments and intensive blood glucose monitoring. Insulin is partially cleared by the kidneys, and decreased renal function can lead to a longer duration of insulin action, increasing the risk of hypoglycemia.

Hepatic Impairment

Patients with liver disease (hepatic impairment) may also require dose adjustments. The liver plays a role in glucose production and insulin metabolism. Close monitoring is essential to prevent hypoglycemia in this population.

Elderly Patients

In patients 65 years and older, the initial dosing, increments, and maintenance dosage should be conservative. The risk of hypoglycemia is higher in the elderly due to potential co-morbidities and age-related declines in renal function.

1. 1Administration: Inject Insulin Degludec subcutaneously (under the skin) once daily at any time of day. While it is best to take it at the same time each day, its long duration allows for flexibility; however, there should be at least 8 hours between injections.
2. 2Injection Sites: Use the thigh, upper arm, or abdomen. Always rotate injection sites within the same region to reduce the risk of lipodystrophy (pitting or thickening of the skin) and localized cutaneous amyloidosis (skin lumps).
3. 3Preparation: Always check the insulin label to ensure you have the correct type and strength. The solution should be clear and colorless. Do not use if it is cloudy or contains particles.
4. 4Technique: If using a FlexTouch pen, always use a new needle for each injection to prevent contamination and needle clogs. Never share your pen or needles with another person, even if the needle is changed.
5. 5Storage: Store unused pens/vials in the refrigerator (36°F to 46°F). Once in use, pens and vials can be kept at room temperature (up to 86°F) or in the refrigerator for up to 56 days. Keep away from direct heat and light. Do not freeze.

If you miss a dose of Insulin Degludec, take it as soon as you remember, ensuring there are at least 8 hours between that dose and your next scheduled dose. Resume your regular once-daily dosing schedule thereafter. Do not take two doses at once to make up for a missed dose.

An overdose of insulin can lead to severe and potentially life-threatening hypoglycemia (low blood sugar) or hypokalemia (low potassium levels).

• Symptoms: Extreme weakness, confusion, tremors, sweating, rapid heartbeat, blurred vision, seizure, or loss of consciousness.
• Action: For mild hypoglycemia, consume fast-acting carbohydrates (glucose tablets, juice). For severe hypoglycemia where the patient cannot swallow, glucagon should be administered by a caregiver, or emergency medical services should be called immediately.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking Insulin Degludec without medical guidance.

The most frequently reported adverse reaction associated with Insulin Degludec is hypoglycemia (low blood sugar). Because Insulin Degludec is a potent glucose-lowering agent, nearly all patients will experience episodes of mild hypoglycemia at some point during treatment.

• Symptoms of Hypoglycemia: These include dizziness, lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, or hunger.
• Duration: Mild episodes usually resolve within 15–30 minutes after consuming 15 grams of fast-acting carbohydrates.
• Upper Respiratory Tract Infections: Some patients report symptoms similar to a common cold, including sore throat and runny nose, during the initial weeks of therapy.

• Injection Site Reactions: Patients may experience redness, swelling, itching, or pain at the site where the insulin was injected. These reactions are usually transient and disappear within a few days to weeks.
• Lipodystrophy: This refers to changes in the skin at the injection site, such as thickening (lipohypertrophy) or pitting (lipoatrophy). This can interfere with insulin absorption. Rotating injection sites is the primary way to prevent this.
• Weight Gain: As glycemic control improves and glucose is no longer lost in the urine, many patients experience weight gain. This is a common effect of all insulin therapies.
• Peripheral Edema: Some patients may notice swelling in their hands, ankles, or feet due to fluid retention. This is often temporary and may occur when starting insulin or during periods of rapid improvement in blood sugar control.

• Severe Hypersensitivity: Generalized allergic reactions, including skin rash over the whole body, shortness of breath, wheezing, fast pulse, or a drop in blood pressure.
• Hypokalemia: Insulin can cause a shift in potassium from the blood into the cells, leading to low potassium levels in the blood. If left untreated, this can cause respiratory paralysis, ventricular arrhythmia, and death.
• Localized Cutaneous Amyloidosis: The formation of lumps under the skin caused by the buildup of amyloid proteins at injection sites. Injecting into these lumps can lead to poor blood sugar control.

> Warning: Stop taking Insulin Degludec and call your doctor immediately if you experience any of these serious symptoms:

1. 1Severe Hypoglycemia: If you feel you are about to pass out, experience a seizure, or have extreme confusion that prevents you from treating yourself.
2. 2Anaphylaxis (Severe Allergic Reaction): Swelling of the face, tongue, or throat; difficulty breathing; or feeling like your heart is racing.
3. 3Signs of Hypokalemia: Severe muscle cramps, extreme weakness, or an irregular heartbeat (arrhythmia).
4. 4Heart Failure Symptoms: If used in combination with certain other diabetes medications (like TZDs), watch for sudden weight gain, shortness of breath, or swelling in the legs and feet.

With prolonged use, the most significant long-term concern is the management of weight and the potential for injection site skin changes. Chronic use of insulin requires diligent rotation of injection sites to maintain consistent absorption. There is no evidence that Insulin Degludec increases the risk of cardiovascular events or cancer over long periods; in fact, the DEVOTE trial (2017) demonstrated cardiovascular safety and a lower rate of nocturnal hypoglycemia over long-term use compared to insulin glargine.

No FDA black box warnings currently exist for Insulin Degludec. However, it carries significant warnings regarding the risk of hypoglycemia and the danger of sharing insulin pens between patients, which can lead to the transmission of bloodborne pathogens.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately to ensure your treatment plan remains safe and effective.

Insulin Degludec is a high-alert medication. Errors in dosing or administration can lead to severe medical complications. Patients must be educated on the signs of both high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia). It is critical to never share an Insulin Degludec FlexTouch pen or needles with another person, even if the needle is changed, as this poses a high risk for spreading infections like hepatitis or HIV.

There are currently no FDA black box warnings for Insulin Degludec. It is considered a safe and effective medication when used according to the prescribed guidelines and monitored by a healthcare professional.

• Hypoglycemia Risk: This is the most common adverse effect. Changes in insulin regimen, meal patterns, physical activity, or co-administered medications may increase the risk. Severe hypoglycemia can lead to unconsciousness, seizures, or death.
• Hypokalemia (Low Potassium): All insulin products, including Degludec, cause a shift in potassium from the extracellular to the intracellular space. This can lead to hypokalemia. Patients at risk (e.g., those using potassium-lowering medications) should have their potassium levels monitored.
• Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. If a reaction is suspected, discontinue use and seek immediate medical care.
• Fluid Retention and Heart Failure: When used in combination with Thiazolidinediones (TZDs), such as pioglitazone, patients should be observed for signs of heart failure. If heart failure develops, dosage reduction or discontinuation of the TZD may be necessary.
• Avoidance of Medication Errors: Accidental mix-ups between Insulin Degludec and other insulins (especially rapid-acting insulins) have been reported. Always check the insulin label before each injection.

Regular monitoring is essential for safety and efficacy:

• Blood Glucose: Self-monitoring of blood glucose (SMBG) is required for all patients. Continuous Glucose Monitoring (CGM) is often recommended for better oversight.
• HbA1c: Hemoglobin A1c should be checked every 3 to 6 months to assess long-term glycemic control.
• Potassium Levels: Should be monitored in patients at risk for hypokalemia.
• Renal and Hepatic Function: Baseline and periodic tests of kidney and liver function are advised, as these organs affect insulin requirements.
• Skin Inspection: Regular inspection of injection sites for lipodystrophy or lumps.

Your ability to concentrate or react may be impaired if you have hypoglycemia. Do not drive or operate heavy machinery until you know how Insulin Degludec affects you and until your blood sugar levels are stable. Always check your blood sugar before driving long distances.

Alcohol can either increase or decrease the blood-glucose-lowering effect of insulin. It can also mask the warning signs of hypoglycemia and may lead to delayed, severe low blood sugar. If you choose to drink alcohol, do so in moderation and always consume food with your drink. Consult your doctor for specific guidance.

Never stop taking Insulin Degludec abruptly unless directed by your doctor. For Type 1 diabetics, stopping insulin can lead to Diabetic Ketoacidosis (DKA), a life-threatening condition. If the medication must be discontinued, your healthcare provider will provide a transition plan to another insulin product.

> Important: Discuss all your medical conditions, including any history of heart, kidney, or liver disease, with your healthcare provider before starting Insulin Degludec.

While there are no absolute drug-drug contraindications that strictly forbid the use of Insulin Degludec, it should never be used during episodes of hypoglycemia. Additionally, the use of Rosiglitazone or Pioglitazone (TZDs) in patients with symptomatic heart failure is generally avoided in combination with insulin due to the high risk of fluid overload and exacerbation of heart failure symptoms.

Several classes of drugs can significantly alter the effect of Insulin Degludec, requiring close monitoring and potential dose adjustments:

• Other Antidiabetic Agents: Combining Degludec with sulfonylureas (e.g., glipizide) or meglitinides increases the risk of hypoglycemia.
• ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs): These blood pressure medications may enhance the glucose-lowering effect of insulin, increasing the risk of 'lows'.
• Monoamine Oxidase Inhibitors (MAOIs): Used for depression, these can potentiate the effects of insulin.
• Fibrates: Used for high cholesterol, these may lower blood glucose levels.
• Pramlintide: This injectable diabetes medication slows gastric emptying and can significantly increase the risk of post-meal hypoglycemia when used with insulin.

• Corticosteroids (e.g., Prednisone): These medications increase blood sugar levels (hyperglycemia), often requiring a significant increase in the Insulin Degludec dose.
• Atypical Antipsychotics (e.g., Olanzapine, Quetiapine): These can cause insulin resistance and elevated blood glucose.
• Diuretics (e.g., Thiazides): May decrease the glucose-lowering effect of insulin.
• Estrogens and Progestogens: Oral contraceptives may reduce insulin sensitivity in some women.
• Beta-Blockers: These are particularly tricky because they can mask the symptoms of hypoglycemia (such as fast heartbeat and tremors), making it difficult for the patient to realize their blood sugar is low.

• Alcohol: As noted, alcohol can prolong the hypoglycemic effect of insulin. It interferes with the liver's ability to release glucose into the bloodstream.
• Consistent Carbohydrate Intake: While not a direct 'interaction', inconsistent meal timing or carbohydrate content can lead to unpredictable blood sugar fluctuations while on basal insulin.

• Fenugreek, Ginseng, and Aloe Vera: These supplements may have mild glucose-lowering properties and could theoretically increase the risk of hypoglycemia when combined with Insulin Degludec.
• Chromium: Some studies suggest chromium may enhance insulin sensitivity, potentially necessitating a lower insulin dose.

Insulin Degludec does not typically interfere with standard laboratory tests. However, it will naturally lower blood glucose and HbA1c levels, which are the intended therapeutic targets. It may also lead to lower serum potassium readings.

Mechanism of Interactions: Most interactions occur via pharmacodynamic mechanisms, where the second drug either mimics insulin's effect (increasing hypoglycemia risk) or opposes it (causing hyperglycemia). Unlike many oral drugs, Insulin Degludec does not rely on the CYP450 liver enzyme system for metabolism, so pharmacokinetic interactions involving enzyme inhibition or induction are rare.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep an updated list to share at every medical appointment.

Insulin Degludec must NEVER be used in the following circumstances:

1. 1During Episodes of Hypoglycemia: If your blood sugar is already low, administering Insulin Degludec will further lower it, potentially leading to coma or death. The medication should only be administered when blood glucose is within or above the target range.
2. 2Hypersensitivity to Insulin Degludec: If you have had a previous severe allergic reaction (anaphylaxis, angioedema, or generalized hives) specifically to Insulin Degludec or any of its excipients (such as glycerol, phenol, metacresol, or zinc acetate), you must not use this product. The mechanism is an IgE-mediated immune response that can be life-threatening.
3. 3Diabetic Ketoacidosis (DKA): Insulin Degludec is not intended for the treatment of DKA. DKA requires rapid-acting intravenous insulin and intensive monitoring in a hospital setting. While a patient with DKA will eventually need basal insulin, Degludec's slow onset makes it inappropriate for acute management.

Conditions requiring careful risk-benefit analysis before using Insulin Degludec include:

• Severe Renal or Hepatic Impairment: While not strictly forbidden, the risk of unpredictable and prolonged hypoglycemia is much higher. Doctors must use extreme caution and frequent monitoring.
• Hypokalemia: If a patient already has low potassium levels, starting insulin can drive potassium levels even lower, risking cardiac arrest. Potassium should be corrected before or during insulin initiation.
• Congestive Heart Failure: Especially if the patient is also taking Thiazolidinediones, the risk of fluid retention may outweigh the benefits of this specific insulin analog.

Patients who have had allergic reactions to other insulin analogs (like Insulin Glargine or Insulin Detemir) should be monitored closely when starting Insulin Degludec. While the chemical structures are different, there is a theoretical risk of cross-reactivity to common preservatives used in insulin formulations, such as metacresol.

> Important: Your healthcare provider will evaluate your complete medical history and current health status before prescribing Insulin Degludec to ensure it is the safest option for you.

Data on the use of Insulin Degludec in pregnant women are limited. However, maintaining good glycemic control during pregnancy is vital, as poorly controlled diabetes increases the risk of birth defects, stillbirth, and macrosomia (large birth weight).

• Risk Summary: Available data from randomized controlled trials have not identified a drug-associated risk of major birth defects or miscarriage.
• Clinical Considerations: Insulin requirements often decrease during the first trimester and increase significantly during the second and third trimesters.
• FDA Category: The FDA no longer uses the A, B, C, D, X categories, but historically, most insulins were Category B or C. Degludec is generally considered acceptable when the benefits of blood sugar control outweigh potential risks, but many doctors still prefer older insulins with more longitudinal data (like Insulin Detemir) for pregnancy.

It is generally considered safe to use Insulin Degludec while breastfeeding. Insulin is a large protein molecule that is naturally present in human milk. Even if small amounts of Insulin Degludec pass into breast milk, it would likely be degraded in the infant's digestive tract and not absorbed into the baby's bloodstream. Breastfeeding mothers may find that their insulin requirements change, often decreasing, due to the energy expenditure of milk production.

Insulin Degludec is approved for use in pediatric patients aged 1 year and older with both Type 1 and Type 2 diabetes.

• Efficacy: Clinical trials have shown that it is as effective as other basal insulins in children, with a lower risk of nocturnal hypoglycemia in some studies.
• Growth: There is no evidence that Insulin Degludec negatively impacts growth or development in children.
• Safety: It is not approved for infants under 12 months of age due to a lack of safety data.

In clinical trials, a large number of patients over 65 used Insulin Degludec.

• Hypoglycemia: The elderly are at higher risk for hypoglycemia because they may not recognize the early warning signs (hypoglycemia unawareness).
• Renal Function: Since kidney function often declines with age, and insulin is partially cleared by the kidneys, the risk of drug accumulation and subsequent low blood sugar is higher.
• Dosing: Doctors usually start with lower doses and increase them more slowly in this population.

No formal pharmacokinetic studies have been conducted specifically for renal impairment with Degludec, but clinical experience shows that insulin requirements decrease as kidney function (measured by GFR) declines. Patients on dialysis may have highly variable insulin needs and require intensive monitoring.

In patients with hepatic impairment, the body's ability to produce glucose and break down insulin is altered. This increases the risk of hypoglycemia. Dose adjustments should be made based on frequent blood glucose readings rather than a standardized formula.

> Important: Special populations require individualized medical assessment and more frequent contact with their diabetes care team.

Insulin Degludec is an ultra-long-acting basal insulin analog. Its primary action is the regulation of glucose metabolism. It binds to the insulin receptor, stimulating tyrosine kinase activity. This triggers a signaling cascade that results in the translocation of glucose transporter proteins (GLUT4) to the cell surface of muscle and adipose tissues. This allows glucose to enter the cells. Additionally, it inhibits hepatic glucose output by suppressing gluconeogenesis and glycogenolysis. The unique 'ultra-long' nature is due to the B29 lysine substitution with a fatty acid side chain, which promotes the formation of stable multi-hexamers in subcutaneous tissue.

The pharmacodynamic profile of Insulin Degludec is characterized by a stable, peakless glucose-lowering effect that lasts for more than 42 hours. This is significantly longer than the 24-hour window of first-generation basal insulins. This 'flat' profile reduces the variability in blood sugar levels from day to day. Tolerance does not typically develop; the drug remains effective as long as the patient's underlying insulin sensitivity does not change drastically.

| Parameter | Value |

|---|---|

| Bioavailability | High (Subcutaneous) |

| Protein Binding | >99% (to Albumin) |

| Half-life | ~25 hours |

| Tmax | ~9 hours (at steady state) |

| Metabolism | Proteolytic degradation (no CYP involvement) |

| Excretion | Cellular degradation; minimal renal/fecal excretion |

• Molecular Formula: C274H411N65O81S6
• Molecular Weight: ~6103.97 Daltons
• Solubility: Soluble in aqueous solutions at physiological pH.
• Structure: A modified human insulin where the threonine at position B30 is deleted and the lysine at B29 is conjugated to hexadecanedioic acid via a gamma-L-glutamyl spacer.

Insulin Degludec is classified as an Insulin Analog [EPC]. It is specifically an ultra-long-acting basal insulin. Related medications include Insulin Glargine (Lantus, Toujeo) and Insulin Detemir (Levemir), though Degludec has a longer duration of action than both.